Neoplasma Vol.62, No.4, p.550-559, 2015
|
| Title: Upregulation of microRNA-200a associates with tumor proliferation,
CSCs phenotype and chemosensitivity in ovarian cancer |
| Author: N. LIU, L. ZHONG, J. ZENG, X. ZHANG, Q. YANG, D. LIAO, Y. WANG, G. CHEN, Y. WANG |
|
Abstract: Ovarian cancer is a lethal gynecologic malignancy and always has a poor prognosis. Despite new treatments modalities, the long term outcomes had not been significantly improved in the past 30 years. Although microRNA-200a (miR-200a) has been reported to be a prognostic marker in ovarian cancer, it’s exact role in ovarian cancer remain unclear. In this study, we inserted the response element of miR-200a in ovarian cancer cell line via lentivirus-mediated transgene in vitro, and qRT-PCR (real time quantitative reverse transcription PCR) assay confirmed that miR-200a was up regulated compared with control. Then colony-formation assay, cell cycle analysis, CCK8 assays in vitro and xenograft experiments in vivo were performed and verified that miR-200a promoted proliferation, while blocked the formation of tumor spheroids and reduced the ratio of SP (side population) cells in ovarian cancer. Finally, we invalidated that miR-200a significantly enhanced the chemosensitivity of paclitaxel but not cisplatin in both adherent culture and sphere culture. Taken together, we demonstrated that upregulation miR-200a promoted proliferation and inhibited CSCs phenotype in OVCAR-3 ovarian cancer cell line, combined with cell cycle-targeting drug paclitaxel could effectively eliminate the “side effects” of proliferation, and showed evidences that this strategy may be promising for ovarian cancer treatment.
|
|
| Keywords: microRNA, ovarian cancer, proliferation, cancer stem cells, chemosensitivity |
|
|
Published online: 18-May-2015
|
| Year: 2015, Volume: 62, Issue: 4 |
Page From: 550, Page To: 559 |
doi:10.4149/neo_2015_066
|
|
 download file |
|
|
|
|
